Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MYC | P01106 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2902887 | 0.80 | KDM4E (0.33) | ALDH1A1POLBKDM4EGLAGAA | |
| SCHEMBL3002544 | 0.78 | KDM4E (0.37) | ALDH1A1KDM4EGAAMAPT | |
| SCHEMBL3586670 | 0.75 | KEAP1 (0.37) | KDM4E | |
| SCHEMBL3574019 | 0.75 | ALDH1A1 (0.40) | ALDH1A1POLBMYCKDM4ETP53 | |
| SCHEMBL3009294 | 0.74 | LCK (0.49) | ALDH1A1POLBMYCKDM4EGAA | |
| SCHEMBL2899363 | 0.68 | NEU3 (0.45) | POLBMYCKDM4ETP53GAA | |
| SCHEMBL1110888 | 0.65 | ALDH1A1 (0.50) | ALDH1A1POLBMYCKDM4EGAA | |
| SCHEMBL9492204 | 0.65 | KEAP1 (0.38) | ALDH1A1POLBKDM4ETP53MAPT | |
| SCHEMBL6647328 | 0.63 | LCK (0.56) | ALDH1A1MYCKDM4EMAPT | |
| SCHEMBL472303 | 0.63 | IDO1 (0.53) | ALDH1A1POLBMYCKDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298324-A1 | Prolyl Hydroxylase Inhibitors | SMITH KLINE BEECHAM CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2240178-A1 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009086044-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITH KLINE BEECHAM CORPORATION (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298324-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | ALDH1A1 204/4885POLB 1480/4885MYC 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.